These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 37728864)

  • 1. Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification.
    Cummings JL; Osse AML; Kinney JW
    Drugs; 2023 Oct; 83(15):1387-1408. PubMed ID: 37728864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates.
    Hroudová J; Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Aug; 134():111069. PubMed ID: 38917881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease drug development pipeline: 2020.
    Cummings J; Lee G; Ritter A; Sabbagh M; Zhong K
    Alzheimers Dement (N Y); 2020; 6(1):e12050. PubMed ID: 32695874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease drug development pipeline: 2023.
    Cummings J; Zhou Y; Lee G; Zhong K; Fonseca J; Cheng F
    Alzheimers Dement (N Y); 2023; 9(2):e12385. PubMed ID: 37251912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease drug development pipeline: 2021.
    Cummings J; Lee G; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2021; 7(1):e12179. PubMed ID: 34095440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Cummings J; Zhou Y; Lee G; Zhong K; Fonseca J; Cheng F
    Alzheimers Dement (N Y); 2024; 10(2):e12465. PubMed ID: 38659717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Alzheimer's disease drug development landscape.
    van Bokhoven P; de Wilde A; Vermunt L; Leferink PS; Heetveld S; Cummings J; Scheltens P; Vijverberg EGB
    Alzheimers Res Ther; 2021 Nov; 13(1):186. PubMed ID: 34763720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease.
    Anand K; Sabbagh M
    Expert Opin Investig Drugs; 2015; 24(10):1355-60. PubMed ID: 26289787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
    Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M
    J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):683-695. PubMed ID: 28490260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational drugs in Alzheimer's disease: current progress.
    Berk C; Paul G; Sabbagh M
    Expert Opin Investig Drugs; 2014 Jun; 23(6):837-46. PubMed ID: 24702504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease.
    Refolo LM; Fillit HM
    J Mol Neurosci; 2004; 23(3):151-5. PubMed ID: 15181243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E4 serum concentration for increased sensitivity and specificity of diagnosis of drug treated Alzheimer's disease patients vs. drug treated parkinson's disease patients vs. age-matched normal controls.
    Goldknopf IL; Park HR; Sabbagh M
    Curr Alzheimer Res; 2012 Dec; 9(10):1149-67. PubMed ID: 22950864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015.
    Mehta D; Jackson R; Paul G; Shi J; Sabbagh M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):735-739. PubMed ID: 28460541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
    Chételat G; Fouquet M
    Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.
    Cummings J; Blennow K; Johnson K; Keeley M; Bateman RJ; Molinuevo JL; Touchon J; Aisen P; Vellas B
    J Prev Alzheimers Dis; 2019; 6(3):157-163. PubMed ID: 31062825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease.
    Mahley RW; Huang Y; Weisgraber KH
    Curr Alzheimer Res; 2007 Dec; 4(5):537-40. PubMed ID: 18220516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.